Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | ANXA2 | P07355 | 1/20 | 0.36 |
| ▸ | S100A10 | P60903 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 9/20 | 0.36 |
| ▸ | CA1 | P00915 | 7/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.34 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | CTSC | P53634 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7115015 | 0.90 | CA2 (0.42) | CHRNA7CCR2CA2CA1CA12 | |
| SCHEMBL7125274 | 0.86 | CHRNA7 (0.43) | CHRNA7EZH2CCR2 | |
| SCHEMBL7124028 | 0.85 | CHRNA7 (0.43) | CHRNA7EZH2CCR2 | |
| SCHEMBL7121781 | 0.85 | CHRNA7 (0.44) | CHRNA7EZH2 | |
| SCHEMBL7127524 | 0.84 | CHRNA7 (0.55) | CHRNA7NPC1EZH2 | |
| SCHEMBL7127459 | 0.84 | CHRNA7 (0.43) | CHRNA7NPC1EZH2 | |
| SCHEMBL7226786 | 0.83 | HSD17B1 (0.35) | NPC1CA2CA1CTSKCTSC | |
| SCHEMBL7120639 | 0.83 | CHRNA7 (0.43) | CHRNA7EZH2CCR2 | |
| SCHEMBL7115057 | 0.83 | HTT (0.44) | CHRNA7EZH2 | |
| SCHEMBL7127363 | 0.82 | MEN1 (0.44) | NPC1EZH2CCR2CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-10 | — | — | US | claimed |
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | CYP7B1, UGT2B7, CYP1B1 | CHRNA7 397/4885NPC1 267/4885EZH2 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.